News
Q2 2025 Earnings Conference Call August 6, 2025 10:00 AM ETCompany ParticipantsBlaine Browers - Chief Financial ...
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces ...
Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results